Zydus Life Science Share Price Today | Stock Price & Zydus Life Science Share Screener
As of October 21, 2026, the live Zydus Life Science share price (NSE: ZYDUSLIFE) is ₹1,117.30 on NSE and ₹1,117.30 on BSE, up 0.31% from the previous close, with shares trading between ₹1,106.00 and ₹1,126.90 in today's trading session, and a 52-week range of ₹860.60–₹1,215.00. Check ZYDUSLIFE 52-week chart for the annual price range and momentum. Use the Zydus Life Science stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Zydus Life Science opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹7,908 and net income of ₹990, with EBITDA of ₹1,802, an operating margin of 22.0% and a profit margin of 12.5%.
Zydus Life Science Share Price Chart
Track the current stock price of Zydus Life Science with an interactive chart. Analyse ZYDUSLIFE share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Zydus Life Science stock quote in one place.
The quote of ₹1,117.30 sits between the 52-week low of ₹860.60 and the 52-week high of ₹1,215.00, and the latest session moved 0.31% from the previous close.
Zydus Life Science Company Profile - Fundamental Screener
Screen Zydus Life Science company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for ZYDUSLIFE shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, with Pankaj R Patel listed as chairperson or CEO, and it trades under ISIN INE010B01027.
Business Overview
Zydus Lifesciences Limited is an Indian global life sciences company that discovers, develops, manufactures, and markets healthcare therapies. Its product portfolio includes active pharmaceutical ingredients, human formulations, animal health products, and wellness products. The company operates in pharmaceuticals, covering human and veterinary formulations, bulk drugs, diagnostics, herbal products, skin care,...more
Company Details
Classification
Identifiers and Leadership
Zydus Life Science Balance Sheet Screener
Screen ZYDUSLIFE balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹52,407, up from ₹37,202 in 2025.
Latest statistics put total assets at ₹52,407 and shareholder funds at ₹29,582, with a leverage ratio of 0.31.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 52,407 | 37,202 | 29,281 | 25,756 | 27,795 | 23,885 | 23,687 | 23,483 | 18,065 | 15,221 |
| Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Assets | 24,106 | 13,134 | 12,369 | 11,521 | 12,189 | 12,133 | 12,231 | 12,164 | 6,483 | 5,755 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 7,113 | 1,802 | 1,840 | 541 | 915 | 1,094 | 3,707 | 4,461 | 3,047 | 2,799 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 29,582 | 26,358 | 22,102 | 19,688 | 19,054 | 14,930 | 11,710 | 11,679 | 8,936 | 7,116 |
| Share Capital | 101 | 101 | 101 | 101 | 102 | 102 | 102 | 102 | 102 | 102 |
| Reserves & Surplus | 27,011 | 23,853 | 19,729 | 17,415 | 16,897 | 12,890 | 10,273 | 10,284 | 8,642 | 6,858 |
Zydus Life Science Income Statement Screener - Profit & Revenue Analysis
Screen Zydus Life Science income statement and profit fundamentals. Analyze ZYDUSLIFE quarterly results. Zydus Life Science reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Jun, revenue was ₹7,908 and net profit was ₹990, equal to earnings per unit of ₹9.35, at an operating margin of 22%.
In that period expenses were ₹6,106, interest cost ₹156 and tax ₹316. The next period listed, 2026-Mar, shows revenue of ₹7,569 and net profit of ₹1,341.
| Item | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||||
| Revenue | 7,908 | 7,569 | 6,892 | 6,147 | 6,622 | 6,371 | 5,181 | 5,182 | 6,110 | 5,526 | 4,403 | 4,313 | 5,089 | 4,890 | 4,199 |
| Expenses | 6,106 | 5,430 | 5,133 | 4,142 | 4,485 | 4,622 | 3,882 | 3,776 | 4,124 | 3,903 | 3,403 | 3,224 | 3,650 | 4,359 | 3,301 |
Operating Costs and Margins | |||||||||||||||
| EBITDA | 1,802 | 2,139 | 1,759 | 2,005 | 2,137 | 1,749 | 1,299 | 1,407 | 1,986 | 1,623 | 1,000 | 1,089 | 1,439 | 532 | 898 |
| Operating Profit % | 22.00% | 27.00% | 24.00% | 31.00% | 31.00% | 27.00% | 24.00% | 26.00% | 32.00% | 27.00% | 22.00% | 24.00% | 28.00% | 10.00% | 21.00% |
| Depreciation | 555 | 508 | 360 | 302 | 238 | 238 | 229 | 234 | 215 | 205 | 195 | 184 | 180 | 179 | 182 |
| Interest | 156 | 123 | 130 | 101 | 85 | 77 | 32 | 25 | 32 | 35 | 20 | 9 | 18 | 28 | 33 |
Profit and Earnings | |||||||||||||||
| Profit Before Tax | 1,307 | 1,660 | 1,353 | 1,687 | 1,921 | 1,672 | 1,184 | 1,271 | 1,900 | 1,550 | 947 | 1,006 | 1,328 | 484 | 781 |
| Tax | 316 | 319 | 331 | 449 | 400 | 428 | 158 | 351 | 417 | 304 | 157 | 203 | 195 | 125 | 149 |
| Net Profit | 990 | 1,341 | 1,023 | 1,239 | 1,521 | 1,244 | 1,026 | 920 | 1,483 | 1,246 | 790 | 803 | 1,134 | 358 | 631 |
| EPS | 9.35 | 12.65 | 10.36 | 12.51 | 14.58 | 11.64 | 10.17 | 9.06 | 14.11 | 11.69 | 7.80 | 7.91 | 10.74 | 2.93 | 6.15 |
Zydus Life Science Cash Flow Screener - Liquidity Fundamentals
Screen ZYDUSLIFE cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹2,117, and net cash flow was an inflow of ₹28.
Over the same period, investing activities used ₹7,895 and financing activities provided ₹5,807.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | 2,117 | 6,781 | 3,228 | 2,689 | 2,104 | 3,293 | 2,505 | 1,282 | 919 | 1,312 |
| Investing Activities | -7,895 | -8,363 | -1,492 | 1,178 | 1,137 | -835 | -1,012 | -3,977 | -974 | -2,872 |
Financing and Net Cash | ||||||||||
| Financing Activities | 5,807 | 1,995 | -1,810 | -4,400 | -868 | -2,549 | -1,094 | 1,885 | 52 | 2,316 |
| Net Cash Flow | 28 | 414 | -75 | -534 | 2,373 | -91 | 399 | -811 | -3 | 756 |
Zydus Life Science Shareholding Pattern Screener
See Zydus Life Science shareholding pattern with promoter, FII, and DII holdings. Check Zydus Life Science promoter holding and ownership changes for ZYDUSLIFE on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Sept, promoters held 75.01%, foreign institutions 7.05%, domestic institutions 11.28% and the public 5.30%, spread across 382,067 shareholders.
The shareholder count was 382,067 in 2026-Sept, compared with 403,889 in 2026-Jun.
| Item | 2026-Sept | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 75.01% | 75.01% | 75.00% | 75.00% | 74.99% | 74.99% | 74.99% | 74.98% |
Institutional Investors | ||||||||
| FII Holding | 7.05% | 6.88% | 6.95% | 7.06% | 7.34% | 7.13% | 7.32% | 7.53% |
| DII Holding | 11.28% | 11.27% | 11.20% | 11.09% | 10.86% | 11.13% | 11.01% | 10.65% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 5.30% | 5.45% | 5.54% | 5.54% | 5.49% | 5.46% | 5.41% | 5.47% |
| Other Holding | 1.36% | 1.38% | 1.32% | 1.31% | 1.32% | 1.28% | 1.28% | 1.36% |
| Shareholder Count | 382,067 | 403,889 | 418,314 | 403,266 | 396,105 | 386,127 | 371,619 | 365,356 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Zydus Life Science. Zydus Life Science dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹1.00 per unit for 2026-March, a yield of 0.09%, compared with ₹11.00 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹1.00, ₹11.00 and ₹3.00 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹1.00 | 0.09% |
| 2025-March | ₹11.00 | 1.26% |
| 2024-March | ₹3.00 | 0.34% |
| 2023-March | ₹6.00 | 0.60% |
| 2022-March | ₹2.50 | 0.51% |
| 2021-March | ₹3.50 | 1.00% |
| 2020-March | ₹3.50 | 0.79% |
| 2019-March | ₹3.50 | 1.31% |
| 2018-March | ₹3.50 | 1.01% |
| 2017-March | ₹3.20 | 0.85% |
Zydus Life Science Stock Index Membership - Nifty & Sensex
See which indices include Zydus Life Science stock. Check ZYDUSLIFE index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
The company is listed in 30 indices, including BSE 1000.
Among the benchmarks tracked are BSE 1000, BSE 200 EQUAL WEIGHT, BSE INDEX BSE HC, BSE INDEX BSE200.
Complete Index List
Zydus Life Science Market Events Screener - Corporate Actions
Get Zydus Life Science corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Zydus Life Science stock events that may affect ZYDUSLIFE share price, along with derivatives, futures and options activity and sector gainers.
15 corporate actions are listed, the most recent entry being Annual General Meeting dated August 11, 2026, with a record date of August 11, 2026.
It is followed by Quarterly Result Announcement dated August 11, 2026 and Dividend dated July 24, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-08-11 | 2026-08-11 | Annual General Meeting | NA | 12.90% |
| 2026-08-11 | 2026-08-11 | Quarterly Result Announcement | NA | -2.16% |
| 2026-07-24 | 2026-07-24 | Dividend | ₹ 1.00 /share | 12.38% |
| 2026-05-29 | 2026-06-04 | Buyback | 1260 | -2.65% |
| 2026-05-19 | 2026-05-19 | Quarterly Result Announcement | NA | 5.42% |
| 2026-02-09 | 2026-02-09 | Quarterly Result Announcement | NA | 0.67% |
| 2025-11-06 | 2025-11-06 | Quarterly Result Announcement | NA | -2.96% |
| 2025-08-12 | 2025-08-12 | Quarterly Result Announcement | NA | -1.47% |
| 2025-08-12 | 2025-08-12 | Annual General Meeting | NA | 4.84% |
| 2025-07-25 | 2025-07-25 | Dividend | ₹ 11.00 /share | 7.57% |
| 2025-05-20 | 2025-05-20 | Quarterly Result Announcement | NA | 4.31% |
| 2025-02-05 | 2025-02-05 | Quarterly Result Announcement | NA | -2.16% |
| 2024-11-12 | 2024-11-12 | Quarterly Result Announcement | NA | -3.36% |
| 2024-08-09 | 2024-08-09 | Annual General Meeting | NA | 26.80% |
| 2024-07-26 | 2024-07-26 | Dividend | ₹ 3.00 /share | 19.50% |
Zydus Life Science Competitors Screener - Peer Stocks Comparison
Screen ZYDUSLIFE competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 418,204 | 34.85 | 61,674 | 12.69% | 11,565 | 34.47 |
| Divis Laboratories | 241,231 | 83.68 | 11,067 | 13.95% | 2,568 | 45.19 |
| Torrent Pharmaceuticals | 173,398 | 80.45 | 13,886 | 20.34% | 2,138 | 32.75 |
| Laurus Labs | 111,791 | 102.03 | 6,868 | 22.01% | 890 | 61.47 |
| Zydus Life Science | 111,112 | 24.42 | 27,658 | 17.64% | 5,026 | 42.73 |
| Cipla | 106,969 | 31.90 | 29,045 | 2.24% | 3,870 | 40.05 |
| Dr Reddys Laboratories | 103,709 | 32.30 | 35,059 | 3.90% | 4,158 | 59.92 |
| Aurobindo Pharma | 93,292 | 25.74 | 34,145 | 5.56% | 3,503 | 40.47 |
| Mankind Pharma | 93,067 | 45.45 | 14,636 | 14.85% | 1,938 | 36.17 |
| Lupin | 88,678 | 16.11 | 29,039 | 26.75% | 5,356 | 32.65 |
Zydus Life Science Company Announcements - News & Reports Screener
Screen ZYDUSLIFE latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated .
The next most recent announcements are dated October 19, 2026 and October 18, 2026.
| Date | Update | Actions |
|---|---|---|
| Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter / Half Year Ended On September 30 2026. | - | |
| 2026-10-19 | ESG Rating | - |
| 2026-10-18 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-10-16 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-10-16 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-10-15 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-10-06 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-10-05 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-10-01 | Announcement under Regulation 30 (LODR)-Updates on Joint Venture | - |
| 2026-09-28 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-09-26 | Closure of Trading Window | - |
| 2026-09-26 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-09-24 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-09-22 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-09-11 | Announcement under Regulation 30 (LODR)-Credit Rating | - |
| 2026-09-11 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-09-09 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-09-05 | Settlement Agreement | - |
| 2026-09-01 | Transcript Of The 31St Annual General Meeting | - |
| 2026-08-31 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹1,117.30, within a 52-week range of ₹860.60 to ₹1,215.00. The P/E ratio is 24.42 and the P/B ratio is 4.14, with earnings per unit of ₹50.09. Market capitalisation stands at ₹111,111.95 Cr and the dividend yield is 0.09%. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 22, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.